FundedIQ
Biotechnology

Spark Biopharma: Funding, Investors & Team (Oct 2026)

SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

sparkbiopharma.com LinkedIn Seoul, South Korea 11-50 employees
Total raised
$21.4M
Rounds
1
Latest
Undisclosed round
May 2026

Spark Biopharma has raised $21.4M across 1 funding round on record, the most recent an undisclosed round of $21.4M announced in May 2026.

That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Spark Biopharma Company Profile and Key Stats

Total funding raised
$21.4M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$21.4M in May 2026
Employees
11-50
reported band
Headquarters
Seoul, South Korea

Latest funding round on record: May 2026.

Spark Biopharma Funding Rounds

Date
Round
Amount
Undisclosed round
$21.4M

Spark Biopharma Founders and Leadership Team

Name
Role
Contact
Seung Bum
Founder
Locked

Contact details for the Spark Biopharma team: 1 has a LinkedIn profile.

Start 14-day free trial →

Spark Biopharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,185
$8.1M
310
$5.1M

Spark Biopharma's latest round of $21.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Spark Biopharma in Biotechnology and Seoul

Companies Similar to Spark Biopharma

ArcGen Bioscience is a biopharmaceutical development company

Series A $6.7M

Lego Chem Bioscience , a company created by people with dreams and enthusiasm for global new drug…

Undisclosed round $214M

April Bio is a drug development company that develops antibodies and long-acting biologics.

Undisclosed round $124M

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective…

Undisclosed round $2.4M

LabGenomics is a healthcare company specialized in molecular diagnostics.

Undisclosed round $13.0M

Galaxy operates a pharmaceutical research and development company for the treatment of encephalopathy and…

Undisclosed round $990k

3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through…

Undisclosed round $11.8M

Shaperon is a clinical-stage biotech company that develops inflammasome inhibitors.

Undisclosed round $5.8M

SN BioScience provide nano-formulation screening services for small molecule, oligonucleotide (siRNA, DNA),…

Undisclosed round $9.3M

M-Based develops new alternative material technologies using mushrooms. 🍄 We consider environmental…

Seed $700k

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…

Undisclosed round $94.0M

Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.

Series A —

Spark Biopharma Funding FAQs

What does Spark Biopharma do?

SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

How much funding has Spark Biopharma raised?

Spark Biopharma has raised $21.4M across 1 round on record. The most recent is an undisclosed round of $21.4M announced in May 2026.

When did Spark Biopharma last raise funding?

Spark Biopharma's most recent funding round on record is an undisclosed round of $21.4M, announced in May 2026.

Who founded Spark Biopharma?

FundedIQ lists Seung Bum (Founder) at Spark Biopharma.

Where is Spark Biopharma headquartered?

Spark Biopharma is based in Seoul, Seoul-t'ukpyolsi, South Korea.

How many employees does Spark Biopharma have?

Spark Biopharma is in the 11-50 employee band.

How does Spark Biopharma's funding compare to other Biotechnology startups?

Spark Biopharma's latest round of $21.4M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.

About FundedIQ's Spark Biopharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Spark Biopharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.